Clinical intervntional study of the method of tonifying the kidney, promoting blood flow and eliminating phlegm for preventing congnitive impairment after stroke

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-11001301

Enrollment

Unknown

Registered

2011-03-22

Start date

2011-04-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

VCI

Interventions

Experiment Group:Acetylsalicylic Acid Enteric-coated Tablet+FuFangCongRongYiZhiJiaoNang

Control Group:Acetylsalicylic Acid Enteric-coated Tablet

Eligibility

Sex/Gender

All

Age

60 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Age>=60; 2. Cerebral infarction (cerebral infarction can be confirmmed by CTor MRI ) nearest cerebral infarction can be diagnosed within 3 months; 3. The complaints without congnitie impairment; MMSE>29; MoCA>=26; 4. Sign information consent form and agree to attend the study.

Exclusion criteria

Exclusion criteria: 1. Severe depression, schizophrenosis, severe anxiety disorder, mania, et al; 2. Alzheimer`s dementia, Vascular dementia, Parkinson, Huntington Disease, FIT; 3. With other diseases that can lead to dementia disease; 4. Severe liver and kidney dysfunction; 5. Severe problems of the blood system (Hb<10mg/dL); 6. Insulin dependent diabetes mellitus; 7. Idiopathic epilepsy and antiepileptic therapy; 8. Severe gastrointestinal diseases; 9. Cancer; 10. Severe nerve function, and the patients who can not cooperate in the study.

Design outcomes

Primary

Measure	Time frame
MOCA MMSE;	—

Countries

China

Contacts

Public ContactWen BAI

gxq42@126.com+86 10 88325885

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026